MGMT and vascular neoplasm: Positive results could lead us to a more personalized decision making in glioblastoma treatment, in particular during the chemotherapy stage, allowing prolonged survival times in patients with methylated MGMT and moderate vascular tumors and avoiding toxicity in patients with high vascular tumors.